Adult asthmatics and acid reflux
Study identifier:SD-NEE-0003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A randomized, double-blind, parallel group multicenter efficacy and safety phase IIB pilot study of Esomeprazole 40mg bid versus placebo bid in adult asthmatics treated for 4 months
Medical condition
asthma
Phase
Phase 2
Healthy volunteers
No
Study drug
Esomeprazole, Placebo
Sex
All
Actual Enrollment
1400
Study type
Interventional
Age
18 Years - 70 Years
Date
Study Start Date: 01 Oct 2002
Primary Completion Date: 01 Apr 2004
Study Completion Date: 01 Apr 2004
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: Esomeprazole 40mg twice a day Other Name: Nexium |
| Placebo Comparator: 2 | Drug: Placebo 40mg twice a day |
Contacts
Investigators
Principal Investigator
Paula Fernstrom
Nexium Global Product Director, AstraZeneca
